Jun 26, 2008 - Akorn-Strides, LLC today announced the approvals of two ANDAs for Famotidine Injection USP, 20 mg/2mL Single-Dose Vials and 40 mg/4mL & 200 mg/20mL Multiple-Dose Vials. Akorn-Strides, LLC is a Joint Venture that was formed in 2005 by Akorn, Inc. (NASDAQ: AKRX) and Strides Arcolab Limited (NSE: STAR)(BSE: 532531). The primary mission for the Joint Venture is to develop liquid, lyophilized and dry powder formulations of generic injectable products targeting several therapeutic markets with a major focus on anti-infectives, analgesics and CNS medicines.
Famotidine Injection is indicated for the short term treatment of duodenal and gastric ulcers and gastroesophageal reflux disease (GERD). Famotidine Injection is therapeutically equivalent to the brand product Pepcid Injection of Merck. Recent IMS data estimates an annual market size of approximately $8 million.
The details can be read here.
No comments:
Post a Comment